Cargando…
Predictive toxicology : from vision to reality /
Tailored to the needs of drug developers, this one-stop reference for medicinal chemists covers all the latest developments in the field of predictive toxicology and its applications in safety assessment. With a keen emphasis on novel approaches, the topics have been tackled by selected expert scien...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Weinheim, Germany :
Wiley-VCH,
[2015]
|
| Colección: | Methods and principles in medicinal chemistry ;
v. 64. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ma 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn896838133 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||uuu|| | ||
| 008 | 141025t20152015gw a ob 001 0 eng d | ||
| 040 | |a YDXCP |b eng |e pn |c YDXCP |d OCLCQ |d COO |d OCLCQ |d OCLCF |d OCLCO |d OCLCA |d E7B |d COCUF |d EBLCP |d DG1 |d N$T |d OHI |d DEBSZ |d DEBBG |d S4S |d GZM |d MOR |d CCO |d LIP |d PIFAG |d ZCU |d MERUC |d U3W |d STF |d ICG |d INT |d VT2 |d AU@ |d WYU |d TKN |d GZM |d OCLCQ |d OCLCO |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d OCLCO |d UKAHL |d UX1 |d OCLCQ |d OCLCA |d VLY |d S2H |d VHC |d OCLCO |d OCLCQ |d OCL |d OCLCO | ||
| 066 | |c (S | ||
| 015 | |a GBB4C7784 |2 bnb | ||
| 016 | 7 | |a 1051706858 |2 DE-101 | |
| 016 | 7 | |a 016940892 |2 Uk | |
| 016 | 7 | |a 1051706858 |2 GyFmDB | |
| 019 | |a 893739321 |a 896838702 |a 981896494 |a 990562852 |a 1055354261 |a 1066626212 |a 1081206932 |a 1162323592 |a 1228616399 |a 1244442458 |a 1249239334 |a 1290110770 |a 1303508349 | ||
| 020 | |a 9783527674190 |q (electronic bk.) | ||
| 020 | |a 3527674195 |q (electronic bk.) | ||
| 020 | |a 9783527674183 |q (electronic bk.) | ||
| 020 | |a 3527674187 |q (electronic bk.) | ||
| 020 | |a 9783527674206 |q (electronic bk.) | ||
| 020 | |a 3527674209 |q (electronic bk.) | ||
| 020 | |a 9783527336081 | ||
| 020 | |a 3527336087 | ||
| 020 | |a 9783527674213 |q (Mobi) | ||
| 020 | |a 3527674217 |q (Mobi) | ||
| 029 | 1 | |a AU@ |b 000056026145 | |
| 029 | 1 | |a CHBIS |b 010441715 | |
| 029 | 1 | |a CHNEW |b 000943655 | |
| 029 | 1 | |a CHVBK |b 480238812 | |
| 029 | 1 | |a DEBBG |b BV042794227 | |
| 029 | 1 | |a DEBBG |b BV043397226 | |
| 029 | 1 | |a DEBBG |b BV044186007 | |
| 029 | 1 | |a DEBSZ |b 431801037 | |
| 029 | 1 | |a DEBSZ |b 485053020 | |
| 029 | 1 | |a NZ1 |b 15910036 | |
| 035 | |a (OCoLC)896838133 |z (OCoLC)893739321 |z (OCoLC)896838702 |z (OCoLC)981896494 |z (OCoLC)990562852 |z (OCoLC)1055354261 |z (OCoLC)1066626212 |z (OCoLC)1081206932 |z (OCoLC)1162323592 |z (OCoLC)1228616399 |z (OCoLC)1244442458 |z (OCoLC)1249239334 |z (OCoLC)1290110770 |z (OCoLC)1303508349 | ||
| 050 | 4 | |a RA1238 |b .P74 2015 | |
| 060 | 4 | |a W1 |b ME9613H v.64 2014 | |
| 060 | 4 | |a QV 600 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a RS |2 lcco | |
| 082 | 0 | 4 | |a 615.9 |2 23 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Predictive toxicology : |b from vision to reality / |c edited by Friedlieb Pfannkuch and Laura Suter-Dick. |
| 264 | 1 | |a Weinheim, Germany : |b Wiley-VCH, |c [2015] | |
| 264 | 4 | |c ©2015 | |
| 300 | |a 1 online resource (xxv, 404 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Methods and Principles in Medicinal Chemistry ; |v v. 64 | |
| 520 | |a Tailored to the needs of drug developers, this one-stop reference for medicinal chemists covers all the latest developments in the field of predictive toxicology and its applications in safety assessment. With a keen emphasis on novel approaches, the topics have been tackled by selected expert scientists, who are familiar with the theoretical scientific background as well as with the practical application of current methods. Emerging technologies in toxicity assessment are introduced and evaluated in terms of their predictive power, with separate sections on computer predictions and simulation. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Introduction to Predictive Toxicology Tools and Methods / Laura Suter-Dick and Friedlieb Pfannkuch -- In silico toxicology : Current Approaches and Future Perspectives to Predict Toxic Effects with Computational Tools / Thomas Steger-Hartmann -- In silico approaches: Data Management : Bioinformatics / Arnd Brandenburg, Hans Gmuender, and Timo Wittenberger -- Role of Modeling and Simulation in Toxicology Prediction / Antje-Christine Walz, Hans Peter Grimm, Christophe Meille, Antonello Caruso, Neil Parrott, and Thierry Lavé -- Genomic Applications for Assessing Toxicities of Liver and Kidney Injury / Philip Hewitt and Esther Johann -- Use of Toxicogenomics for Mechanistic Characterization of Hepatocarcinogens in Shorter Term Studies / Heidrun Ellinger-Ziegelbauer -- Discovery and Application of Novel Biomarkers / Timothy W. Gant, Emma L. Marczylo, and Martin O. Leonard -- Predictive Toxicology: Genetics, Genomics, Epigenetics, and Next-Generation Sequencing in Toxicology / Tobias Heckel and Laura Suter-Dick -- Biomarkers as Tools for Predictive Safety Assessment: Novel Markers of Drug-Induced Kidney Injury / Angela Mally -- The Use of Renal Cell Culture for Nephrotoxicity Investigations / Anja Wilmes and Paul Jennings -- The Zebrafish Model in Toxicology / Natalie Mesens -- Predictive Method Development: Challenges for Cosmetics and Genotoxicity as a Case Study / Gladys Ouédraogo, Fabrice Nesslany, Sophie Simar, Smail Talahari, Doris Lagache, Eric Vercauteren, Lauren Nakab, Astrid Mayoux, Brigitte Faquet, and Nicole Flamand -- Using Pluripotent Stem Cells and Their Progeny as an in vitro Model to Assess (Developmental) Neurotoxicity / Lisa Hoelting, Marcel Leist, and Luc Stoppini -- Stem Cell-Based Methods for Identifying Developmental Toxicity Potential / Jessica A. Palmer, Robert E. Burrier, Laura A. Egnash, and Elizabeth L.R. Donley -- Immunogenicity of Protein Therapeutics: Risk Assessment and Risk Mitigation / Harald Kropshofer -- Regulatory Aspects / Beatriz Silva Lima. | |
| 588 | 0 | |a Online resource; title from digital title page (viewed on November 24, 2014). | |
| 546 | |a English. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Toxicology. | |
| 650 | 0 | |a Drugs |x Toxicity testing. | |
| 650 | 0 | |a Drug development |x Safety measures. | |
| 650 | 0 | |a Drugs |x Side effects. | |
| 650 | 0 | |a Mathematical models. | |
| 650 | 1 | 2 | |a Drug-Related Side Effects and Adverse Reactions |
| 650 | 1 | 2 | |a Models, Theoretical |
| 650 | 2 | 2 | |a Toxicology |x methods |
| 650 | 2 | 2 | |a Toxicogenetics |x methods |
| 650 | 2 | |a Toxicology | |
| 650 | 6 | |a Toxicologie. | |
| 650 | 6 | |a Médicaments |x Toxicité. | |
| 650 | 6 | |a Médicaments |x Développement |x Sécurité |x Mesures. | |
| 650 | 6 | |a Médicaments |x Effets secondaires. | |
| 650 | 6 | |a Modèles mathématiques. | |
| 650 | 7 | |a toxicology. |2 aat | |
| 650 | 7 | |a mathematical models. |2 aat | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Mathematical models |2 fast | |
| 650 | 7 | |a Drugs |x Side effects |2 fast | |
| 650 | 7 | |a Drugs |x Toxicity testing |2 fast | |
| 650 | 7 | |a Toxicology |2 fast | |
| 700 | 1 | |a Pfannkuch, Friedlieb. | |
| 700 | 1 | |a Suter-Dick, Laura. | |
| 700 | 1 | |a Mannhold, Raimund. | |
| 700 | 1 | |a Kubinyi, Hugo. | |
| 700 | 1 | |a Folkers, Gerd. | |
| 776 | 0 | 8 | |i Print version: |a Pfannkuch, Friedlieb. |t Predictive Toxicology : From Vision to Reality, Volume 64. |d Hoboken : Wiley, ©2014 |z 9783527336081 |
| 830 | 0 | |a Methods and principles in medicinal chemistry ; |v v. 64. | |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=1818243 |z Texto completo |
| 880 | 0 | 0 | |6 505-00/(S |g Contents note continued: |g 4.7. |t Justification of Starting Dose, Calculation of Safety Margins, and Support of Phase I Clinical Trial Design / |r Antje-Christine Walz / |r Hans Peter Grimm / |r Christophe Meille / |r Antonello Caruso / |r Neil Parrott / |r Thierry Lavé -- |g 4.8. |t Outlook and Conclusions / |r Antje-Christine Walz / |r Hans Peter Grimm / |r Christophe Meille / |r Antonello Caruso / |r Neil Parrott / |r Thierry Lavé -- |t References / |r Antje-Christine Walz / |r Hans Peter Grimm / |r Christophe Meille / |r Antonello Caruso / |r Neil Parrott / |r Thierry Lavé -- |g 5.1. |t Introduction / |r Philip Hewitt / |r Esther Johann -- |g 5.1.1. |t Toxicogenomics in Drug Development / |r Philip Hewitt / |r Esther Johann -- |g 5.2. |t Toxicogenomic Approaches / |r Philip Hewitt / |r Esther Johann -- |g 5.2.1. |t High-Throughput Expression Profiles and DNA Microarrays / |r Philip Hewitt / |r Esther Johann -- |g 5.2.2. |t Data Analysis / |r Philip Hewitt / |r Esther Johann -- |g 5.3. |t Specific Applications of Toxicogenomics / |r Philip Hewitt / |r Esther Johann -- |g 5.3.1. |t Mechanistic Toxicogenomics and Risk Assessment / |r Philip Hewitt / |r Esther Johann -- |g 5.3.2. |t Toxicogenomic Profiling of Hepatotoxicity / |r Philip Hewitt / |r Esther Johann -- |g 5.3.2.1. |t Hepatotoxicity in Drug Development / |r Philip Hewitt / |r Esther Johann -- |g 5.3.3. |t Functional and Structural Properties of the Liver / |r Philip Hewitt / |r Esther Johann -- |g 5.3.4. |t Liver Morphology / |r Philip Hewitt / |r Esther Johann -- |g 5.3.5. |t Cell Types / |r Philip Hewitt / |r Esther Johann -- |g 5.3.6. |t Functional Gradients / |r Philip Hewitt / |r Esther Johann -- |g 5.4. |t Toxicogenomic Applications for the Better Understanding of Hepatotoxicity / |r Philip Hewitt / |r Esther Johann -- |g 5.4.1. |t Mechanistic Toxicology / |r Philip Hewitt / |r Esther Johann -- |g 5.4.2. |t Class Identification / |r Philip Hewitt / |r Esther Johann -- |g 5.4.3. |t Predictive Toxicology / |r Philip Hewitt / |r Esther Johann -- |g 5.4.4. |t In Vitro Classifiers of Hepatotoxicity / |r Philip Hewitt / |r Esther Johann -- |g 5.4.5. |t Biomarker Identification / |r Philip Hewitt / |r Esther Johann -- |g 5.5. |t Toxicogenomic Profiling of Nephrotoxicity / |r Philip Hewitt / |r Esther Johann -- |g 5.5.1. |t Toxicogenomic Approaches in Nephrotoxicity / |r Philip Hewitt / |r Esther Johann -- |g 5.5.2. |t Finding Genes that Matter in AKI / |r Philip Hewitt / |r Esther Johann -- |g 5.5.3. |t Searching for New Biomarkers of Kidney Injury / |r Philip Hewitt / |r Esther Johann -- |g 5.6. |t Limitations of Toxicogenomics / |r Philip Hewitt / |r Esther Johann -- |g 5.6.1. |t Idiosyncrasies / |r Philip Hewitt / |r Esther Johann -- |g 5.6.2. |t Epigenetics / |r Philip Hewitt / |r Esther Johann -- |g 5.7. |t Conclusions / |r Philip Hewitt / |r Esther Johann -- |t References / |r Philip Hewitt / |r Esther Johann -- |g 6.1. |t Introduction / |r Heidrun Ellinger-Ziegelbauer -- |g 6.1.1. |t Rodent Carcinogenicity Testing / |r Heidrun Ellinger-Ziegelbauer -- |g 6.1.2. |t Classes of Carcinogens / |r Heidrun Ellinger-Ziegelbauer -- |g 6.2. |t Toxicogenomics / |r Heidrun Ellinger-Ziegelbauer -- |g 6.2.1. |t Mechanistic Toxicogenomic Analysis after Short-Term Treatment with Rodent Hepatocarcinogens / |r Heidrun Ellinger-Ziegelbauer -- |g 6.2.2. |t Approaches for Prediction of Potential Hepatocarcinogens Based on Gene Expression Profiling / |r Heidrun Ellinger-Ziegelbauer -- |g 6.2.3. |t Recent Developments: Transcriptional Benchmark Dose Modeling Based on Functional Analyses / |r Heidrun Ellinger-Ziegelbauer -- |g 6.2.4. |t Recent Opportunities: Publicly Available Data / |r Heidrun Ellinger-Ziegelbauer -- |g 6.3. |t Conclusions and Outlook / |r Heidrun Ellinger-Ziegelbauer -- |t References / |r Heidrun Ellinger-Ziegelbauer -- |g 7.1. |t Introduction / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.1.1. |t New Technologies Give Rise to Novel Opportunities for Biomarker Discovery / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.2. |t Novel RNA Biomarkers / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.2.1. |t Complex RNA Biomarker in Cancer / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.2.2. |t Complex RNA Biomarker in Toxicology / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.2.3. |t Connectivity Mapping with the Complex RNA Biomarker for Hazard Identification / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.2.4. |t miRNA Biomarkers / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.3. |t DNA as a Biomarker / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.3.1. |t DNA Polymorphisms as Future Biomarkers of Disease and Xenobiotic Susceptibility / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.3.2. |t DNA and Protein Adduct Biomarkers / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.3.3. |t Epigenetic Biomarkers / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.4. |t Novel Biomarkers: Beyond Nucleotide-Based Discovery / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 7.5. |t Summary and Outlook / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |t References / |r Timothy W. Gant / |r Emma L. Marczylo / |r Martin O. Leonard -- |g 8.1. |t Introduction / |r Tobias Heckel / |r Laura Suter-Dick -- |g 8.2. |t Technological Advances / |r Tobias Heckel / |r Laura Suter-Dick -- |g 8.3. |t Applications in Toxicology / |r Tobias Heckel / |r Laura Suter-Dick -- |g 8.3.1. |t Genome Sequencing and Sequence Level Comparisons / |r Tobias Heckel / |r Laura Suter-Dick -- |g 8.3.2. |t Genotype and Metabolism / |r Tobias Heckel / |r Laura Suter-Dick -- |g 8.3.3. |t Mechanistic Toxicology and Toxicogenomics / |r Tobias Heckel / |r Laura Suter-Dick -- |g 8.3.4. |t Epigenetic Changes and miRNAs / |r Tobias Heckel / |r Laura Suter-Dick -- |g 8.4. |t Summary and Outlook / |r Tobias Heckel / |r Laura Suter-Dick -- |t References / |r Tobias Heckel / |r Laura Suter-Dick -- |g 9.1. |t Need and Search for Novel Biomarkers of Kidney Injury / |r Angela Mally -- |g 9.2. |t Urinary Biomarkers of Drug-Induced Kidney Injury / |r Angela Mally -- |g 9.2.1. |t Structure and Function of Novel Urinary Biomarkers / |r Angela Mally -- |g 9.2.1.1. |t Kidney Injury Molecule-1 / |r Angela Mally -- |g 9.2.1.2. |t Clusterin / |r Angela Mally -- |g 9.2.1.3. |t Cystatin C / |r Angela Mally -- |g 9.2.1.4. |t β2-Microglobulin / |r Angela Mally -- |g 9.2.1.5. |t Liver-Type Fatty Acid Binding Protein / |r Angela Mally -- |g 9.2.1.6. |t Neutrophil Gelatinase-Associated Lipocalin / |r Angela Mally -- |g 9.2.1.7. |t Others / |r Angela Mally -- |g 9.2.2. |t Experimental and Clinical Support for the Use of Novel Urinary Biomarkers for the Detection and Prediction of Acute Kidney Injury / |r Angela Mally -- |g 9.2.2.1. |t Performance of Novel Urinary Biomarkers in Preclinical Models of Renal Injury / |r Angela Mally -- |g 9.2.2.2. |t Clinical Support for Novel Urinary Kidney Injury Biomarkers / |r Angela Mally -- |g 9.3. |t Genomic Biomarkers / |r Angela Mally -- |g 9.3.1. |t Individual Genes / |r Angela Mally -- |g 9.3.2. |t Biomarker Panels and Gene Signatures / |r Angela Mally -- |g 9.3.3. |t MicroRNAs / |r Angela Mally -- |g 9.4. |t Qualification and Use of Novel Kidney Injury Biomarkers in Preclinical Safety Assessment / |r Angela Mally -- |g 9.4.1. |t Biomarker Qualification and Regulatory Acceptance / |r Angela Mally -- |g 9.4.2. |t Application of Novel Renal Safety Markers to Preclinical Decision Making / |r Angela Mally -- |g 9.4.3. |t Technological Aspects / |r Angela Mally -- |g 9.5. |t Summary and Perspectives / |r Angela Mally -- |t References / |r Angela Mally -- |g 10.1. |t Introduction / |r Anja Wilmes / |r Paul Jennings -- |g 10.2. |t In Vitro Renal Models / |r Anja Wilmes / |r Paul Jennings -- |g 10.2.1. |t Characterization / |r Anja Wilmes / |r Paul Jennings -- |g 10.2.2. |t Immortalization of Primary Cells / |r Anja Wilmes / |r Paul Jennings -- |g 10.2.3. |t Available Podocyte and Proximal Tubule Cell Lines / |r Anja Wilmes / |r Paul Jennings -- |g 10.3. |t Stem Cells / |r Anja Wilmes / |r Paul Jennings -- |g 10.4. |t Optimal Cell Culture Conditions / |r Anja Wilmes / |r Paul Jennings -- |g 10.5. |t In Vitro Nephrotoxicity Assessment / |r Paul Jennings / |r Anja Wilmes -- |g 10.6. |t Outlook / |r Paul Jennings / |r Anja Wilmes -- |t References / |r Paul Jennings / |r Anja Wilmes -- |g 11.1. |t Need for a Physiologically Relevant Organ Model in Drug Toxicity Testing / |r Natalie Mesens -- |g 11.2. |t Extensive Knowledge about Genetics, Development, and Physiology of D. |
| 880 | 0 | 0 | |t rerio / |r Natalie Mesens -- |g 11.3. |t Studies of Specific Organ Toxicities in Zebrafish Embryos and Larvae / |r Natalie Mesens -- |g 11.3.1. |t Cardiotoxicity / |r Natalie Mesens -- |g 11.3.2. |t Neurotoxicity / |r Natalie Mesens -- |g 11.3.3. |t Hepatotoxicity / |r Natalie Mesens -- |g 11.3.4. |t Teratogenicity / |r Natalie Mesens -- |g 11.3.5. |t Future Directions: ADME Studies and Future Explorative Research / |r Natalie Mesens -- |g 11.3.5.1. |t Absorption and Distribution / |r Natalie Mesens -- |g 11.3.5.2. |t Metabolism / |r Natalie Mesens -- |g 11.3.5.3. |t Harmonization and Validation / |r Natalie Mesens -- |g 11.3.5.4. |t Future Explorative Research / |r Natalie Mesens -- |t References / |r Natalie Mesens -- |g 12.1. |t Introduction / |r Gladys Ouédraogo / |r Fabrice Nesslany / |r Sophie Simar / |r Small Talahari / |r Nicole Flamand / |r Eric Vercauteren / |r Lauren Nakab / |r Astrid Mayoux / |r Brigitte Faquet / |r Doris Lagache -- |g 12.2. |t Toolbox of Predictive Methods / |r Gladys Ouédraogo / |r Fabrice Nesslany / |r Sophie Simar / |r Small Talahari / |r Nicole Flamand / |r Eric Vercauteren / |r Lauren Nakab / |r Astrid Mayoux / |r Brigitte Faquet / |r Doris Lagache -- |g 12.2.1. |t In Silico Tools / |r Eric Vercauteren / |r Lauren Nakab / |r Astrid Mayoux / |r Brigitte Faquet / |r Doris Lagache / |r Gladys Ouédraogo / |r Fabrice Nesslany / |r Sophie Simar / |r Small Talahari / |r Nicole Flamand -- |g 12.2.2. |t Biochemical (In Chemico) Assays / |r Gladys Ouédraogo / |r Fabrice Nesslany / |r Sophie Simar / |r Small Talahari / |r Nicole Flamand / |r Eric Vercauteren / |r Lauren Nakab / |r Astrid Mayoux / |r Brigitte Faquet / |r Doris Lagache -- |g 12.2.3. |t In Vitro 2D Assays / |r Gladys Ouédraogo / |r Fabrice Nesslany / |r Sophie Simar / |r Small Talahari / |r Nicole Flamand / |r Eric Vercauteren / |r Lauren Nakab / |r Astrid Mayoux / |r Brigitte Faquet / |r Doris Lagache. |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH27113666 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH27114004 | ||
| 938 | |a YBP Library Services |b YANK |n 12127188 | ||
| 938 | |a YBP Library Services |b YANK |n 12125145 | ||
| 938 | |a YBP Library Services |b YANK |n 11072916 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL1818243 | ||
| 938 | |a ebrary |b EBRY |n ebr10955316 | ||
| 938 | |a EBSCOhost |b EBSC |n 872452 | ||
| 994 | |a 92 |b IZTAP | ||